查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1518475

呼吸道合胞病毒治療市場 - 依藥物類型（帕利珠單抗、利巴韋林、莫他珠單抗）、給藥途徑（口服、注射、鼻內）、病患類型（成人、兒童）、配銷通路與預測，2024 - 2032 年

Respiratory Syncytial Virus Therapeutics Market - By Drugs Type (Palivizumab, Ribavirin, Motavizumab), Route of administration (Oral, Injectable, Intranasal), Patient Type (Adult, Pediatric), Distribution Channel & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在呼吸道感染盛行率不斷上升的推動下，呼吸道合胞病毒治療市場規模在 2024 年至 2032 年期間將以 12.8% 的複合年成長率成長。根據 firsnet.org 報告，慢性阻塞性肺病影響全球近 2 億人，約佔全球人口的 4%，每年導致約 320 萬人死亡。 RSV 感染發生率不斷上升，加上季節性爆發，推動了對有效治療和預防措施的需求。我們正在探索 RSV 病毒學、免疫學和抗病毒藥物發現的持續努力，包括單株抗體、抗病毒藥物和疫苗，旨在提高療效和患者預後。此外，專注於加強 RSV 感染的早期檢測和管理以減輕醫療負擔，這將促進 RSV 療法的普及。

呼吸道合胞病毒治療產業根據藥物類型、給藥途徑、患者類型、配銷通路和地區進行分類。

利巴韋林細分市場將在 2032 年快速成長。它在控制 RSV 感染方面的有效性，特別是在高風險患者群體中，鞏固了其作為基石療法的地位。正在進行的臨床試驗和研究計劃繼續探索利巴韋林的功效和安全性，強調其在 RSV 治療中的重要性。

由於嬰幼兒容易受到嚴重 RSV 感染，兒科細分市場將在 2032 年之前為市場成長創造利潤豐厚的機會。醫療保健提供者強調兒科患者的早期診斷和治療，以預防呼吸窘迫和住院等併發症。兒科專用製劑和疫苗的開發仍然是製藥公司的重點領域，旨在解決這一弱勢患者群體未滿足的醫療需求。

到2032年，歐洲呼吸道合胞病毒治療產業將出現良好成長，其特徵是醫療基礎設施健全和醫療支出高。該地區的人口老化和慢性呼吸道疾病的日益流行增加了對有效 RSV 治療的需求。此外，支持性的政府措施和有利的監管政策透過促進新療法的及時批准、商業化和可及性來促進市場成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 慢性呼吸道疾病盛行率不斷上升
      • 醫療保健支出增加
      • 藥物發現的技術進步
    • 產業陷阱與挑戰
      • 監管障礙和核准挑戰
      • 發展中國家的醫療基礎設施有限
  • 成長潛力分析
  • 監管環境
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

  • 主要趨勢
  • 帕利珠單抗
  • 利巴韋林
  • 莫維珠單抗
  • 其他藥物類型

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

  • 主要趨勢
  • 口服
  • 可注射
  • 鼻內
  • 其他給藥途徑

第 7 章：市場估計與預測：按病患類型，2021 - 2032 年

  • 主要趨勢
  • 成人
  • 兒科

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局和藥局
  • 網路藥局

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Gilead Sciences
  • GSK plc
  • Johnson & Johnson
  • Medivir AB
  • Merck & Co., Inc
  • Pfizer Inc.
  • Sanofi
簡介目錄
Product Code: 9184

The Respiratory Syncytial Virus Therapeutics Market size will grow at 12.8% CAGR during 2024-2032, driven by the increasing prevalence of respiratory infections. According to firsnet.org, COPD affects nearly 200 million people worldwide, representing approximately 4% of the global population, and results in approximately 3.2 million deaths annually. The rising incidence of RSV infections, coupled with seasonal outbreaks, drives the demand for effective therapeutics and preventive measures. Continuous efforts in RSV virology, immunology, and antiviral drug discovery are being explored, including monoclonal antibodies, antiviral agents, and vaccines, aimed at improving efficacy and patient outcomes. Additionally, the focus on enhancing early detection and management of RSV infections in order to reduce healthcare burden will bolster the popularity of RSV therapeutics.

The respiratory syncytial virus therapeutics industry is classified based on drug type, route of administration, patient type, distribution channel and region.

The ribavirin segment will grow rapidly through 2032. Known for its broad-spectrum antiviral activity, Ribavirin is commonly administered via inhalation or intravenous infusion to reduce viral replication and alleviate symptoms associated with RSV. Its effectiveness in managing RSV infections, especially in high-risk patient populations, has solidified its position as a cornerstone therapy. Ongoing clinical trials and research initiatives continue to explore Ribavirin's efficacy and safety profile, underscoring its significance in RSV therapeutics.

The pediatric segment will create lucrative opportunities for market growth through 2032, due to the vulnerability of infants and young children to severe RSV infections. Healthcare providers emphasize early diagnosis and treatment in pediatric patients to prevent complications such as respiratory distress and hospitalization. The development of pediatric-specific formulations and vaccines remains a key focus area for pharmaceutical companies aiming to address unmet medical needs in this vulnerable patient group.

Europe respiratory syncytial virus therapeutics industry will witness decent growth through 2032, characterized by robust healthcare infrastructure and high medical expenditure. The region's aging population and increasing prevalence of chronic respiratory diseases contribute to the demand for effective RSV treatments. Additionally, supportive government initiatives and favorable regulatory policies promote market growth by facilitating timely approvals and commercialization & accessibility of new therapeutics.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic respiratory conditions
      • 3.2.1.2 Rising healthcare expenditure
      • 3.2.1.3 Technological advancements in drug discovery
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Regulatory hurdles and approval challenges
      • 3.2.2.2 Limited healthcare infrastructure in developing countries
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Palivizumab
  • 5.3 Ribavirin
  • 5.4 Motavizumab
  • 5.5 Other drug types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Injectable
  • 6.4 Intranasal
  • 6.5 Other route of administrations

Chapter 7 Market Estimates and Forecast, By Patient Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adult
  • 7.3 Pediatrics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies & drug stores
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 AstraZeneca PLC
  • 10.3 Bausch Health Companies Inc.
  • 10.4 Gilead Sciences
  • 10.5 GSK plc
  • 10.6 Johnson & Johnson
  • 10.7 Medivir AB
  • 10.8 Merck & Co., Inc
  • 10.9 Pfizer Inc.
  • 10.10 Sanofi